Optimal glycaemic targets for women with gestational diabetes: the randomised trial - TARGET
Not Applicable
Completed
- Conditions
- Gestational Diabetes MellitusReproductive Health and Childbirth - Fetal medicine and complications of pregnancyMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12615000282583
- Lead Sponsor
- niversity of Auckland, Research Office
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 1100
Inclusion Criteria
Hospital providing care for women with gestational diabetes diagnosed between 22 weeks' gestation and 34 weeks' gestation.
Exclusion Criteria
Women where the fetus has a major anomaly.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method arge for gestational age infant (defined as birth weight >90th centile using customised charts)[At birth]
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are affected by tight glycaemic control in gestational diabetes mellitus (GDM) to reduce fetal macrosomia?
How does the TARGET trial (ACTRN12615000282583) compare tight glycaemic targets to standard-of-care thresholds in preventing large for gestational age (LGA) infants?
Which biomarkers correlate with improved maternal and fetal outcomes in GDM under strict glycaemic management strategies?
What adverse events are associated with tight glycaemic targets in GDM, and how do they compare to less intensive regimens in the TARGET trial?
Are combination therapies like metformin and insulin more effective than monotherapy in achieving glycaemic targets for GDM as evaluated in ACTRN12615000282583?